Skip to content
    IRWD
    Earnings call· Jun 2026(Q2 FY26)

    IRONWOOD PHARMACEUTICALS Q2 FY26 earnings call IRWD

    Aug 6, 2026 Source

    Executive summary

    Ironwood Pharmaceuticals Q2 FY26 — Strong Linzess Performance and Apraglutide Advancement

    Ironwood Pharmaceuticals delivered a strong second quarter, driven by exceptional Linzess performance with double-digit sales growth and an expanded pediatric indication. The company also advanced its apraglutide pipeline by initiating the confirmatory Phase III STARS II trial. Management raised full-year financial guidance, reflecting confidence in continued execution and expects to further strengthen its balance sheet by reducing debt while investing in apraglutide's commercialization.

    Highlights

    5

    • Linzess U.S. net sales reached $582.3 million in Q2 FY26, a 14% year-over-year increase, driven by demand growth and improved net price.

    • Full-year 2026 Linzess U.S. net sales guidance increased to $1.15 billion - $1.2 billion, projecting over 30% year-over-year growth and a return to blockbuster status.

    • FDA approved LINZESS for functional constipation in pediatric patients 2 years of age and older, establishing it as the only prescription therapy for this age group.

    • Initiated the confirmatory Phase III STARS II clinical trial for apraglutide in SBS-IF, with active patient recruitment and site activation underway.

    • Generated $51.3 million in GAAP net income and $83 million in adjusted EBITDA in Q2 FY26, and repaid $200 million convertible notes at maturity.

    Concerns

    1

    • R&D and SG&A expenses are expected to increase in H2 FY26 due to the ramp-up of the STARS II trial, impacting the bottom line.

    Guidance & targets

    6
    CategoryTargetConfidence
    Linzess U.S. net sales
    $1.15 billion and $1.2 billion
    high materiality
    High
    Total revenue
    $460 million and $485 million
    high materiality
    High
    Adjusted EBITDA
    greater than $310 million
    high materiality
    High
    Gross debt outstanding
    less than $300 million
    medium materiality
    High
    Gross leverage
    below 1x
    medium materiality
    High
    Linzess prescription demand growth
    mid-single-digit
    medium materiality
    High

    Segment performance

    1
    SegmentRevenueYoYQoQMargin
    Linzess
    Linzess continues to be the prescription leader in IBS-C and CIC, with strong performance driven by demand growth and improved net price. The recent FDA approval for functional constipation in pediatric patients further expands its market.
    EUTRX volume growth: 4% YoYEUTRX volume growth YTD: 5%U.S. net sales YTD: $555 millionU.S. net sales YTD growth: 44% YoY
    		$582.3 million14%——

    Operational metrics

    7
    GAAP Net Income
    $51.3 million
    Q2 FY26

    Generated $51.3 million in GAAP net income during the quarter.

    Adjusted EBITDA
    $83 million
    Q2 FY26

    Generated $83 million in adjusted EBITDA during the quarter.

    Cash and cash equivalents
    $79 million
    Q2 FY26 end

    Ended the quarter with $79 million in cash and cash equivalents.

    Collaboration receivables
    $113 million
    Q2 FY26 end

    Ended the quarter with $113 million in collaboration receivables.

    Convertible notes repaid
    $200 million
    June 2026

    Repaid our $200 million convertible notes at maturity with cash on hand.

    R&D expense
    increaserelative to H1 FY26
    H2 FY26

    Expected to increase relative to the first half of the year, reflecting the ramp up of the STARS II trial.

    SG&A expense
    modest increase
    H2 FY26

    Expected to see a modest increase in SG&A expense.

    Industry KPIs

    7
    MetricValueDetails
    Launch access metricsongoing access for patients across channels
    Pipeline read out calendarSTARS II confirmatory Phase III trial initiated
    Product franchise net sales$582.3 millionUSD
    Regulatory approvals filingsFDA approval
    Peak long term sales guidancereturn to blockbuster status
    Prescription volume new starts4%%
    Clinical trial efficacy safety dataSignificant reductions in parenteral support requirements

    Product announcements

    1
    ProductTypeDetails
    LINZESSexpansion

    Risks & headwinds

    2
    Potential demand softening for Linzess due to elimination of inflationary rebates across channels.early in the year

    low single digit demand growth

    Mitigation: Worked with partner to ensure ongoing access for patients across channels, including Medicaid, leading to confidence in mid-single-digit demand growth for the full year.

    Increased R&D and SG&A expenses in the second half of the year.H2 FY26

    increase (R&D), modest increase (SG&A)

    Mitigation: These are critical investments in the future, particularly for the STARS II trial ramp-up, and will depend on the speed of site activation.

    What to watch in Q3 FY26

    5

    Apraglutide STARS II enrollment progress

    coming months
    CurrentActively recruiting patients, activating additional sites
    TargetAccelerated enrollment timeline

    Why it matters

    Successful and timely enrollment is critical for the apraglutide development timeline and potential market entry.

    We look forward to updating you on our progress in the coming months⏳.

    Q&A highlights

    7

    Inquired about the impact of net price changes on Linzess demand, specifically if earlier concerns about demand softening due to elimination of inflationary rebates have been alleviated.

    Management confirmed that year-to-date EUTRX volume demand growth is tracking at 5%, modestly ahead of initial low single-digit projections. They expressed confidence in achieving mid-single-digit demand growth for the full year, attributing it to successful efforts with partners to ensure patient access across channels, including Medicaid.

    “We've done a lot working with our partner to really help ensure ongoing access for patients across channels, and we think we're in a very good spot now to deliver in that mid-single digit range to the full year.”

    asked by Jason Butler · answered by Unknown Speaker

    2 min read7 chapters

    Detailed Narrative

    01

    Strong Linzess Performance and Guidance Raise

    Ironwood reported robust Q2 FY26 Linzess U.S. net sales of $582.3 million, a 14% year-over-year increase, driven by both demand growth and improved net price. Year-to-date sales reached $555 million, up 44%. This strong performance led to an increased full-year 2026 guidance for Linzess U.S. net sales to $1.15 billion - $1.2 billion, projecting over 30% year-over-year growth and a return to blockbuster status.

    02

    Pediatric Approval for Linzess

    A significant regulatory milestone was achieved with the FDA approval of LINZESS for the treatment of functional constipation in pediatric patients 2 years of age and older. This approval establishes LINZESS as the only prescription therapy for this age group, addressing an unmet patient need and further expanding the product's market reach.

    03

    Advancement of Apraglutide with STARS II Initiation

    The company initiated the confirmatory Phase III STARS II clinical trial for apraglutide in adults with short bowel syndrome with intestinal failure (SBS-IF) in June. The trial is actively recruiting patients, with efforts underway to activate additional sites and accelerate enrollment. This trial builds on positive data from the Phase III STARS trial, which demonstrated significant reductions in parenteral support requirements.

    04

    Apraglutide's Differentiated Profile

    Apraglutide is highlighted as the only once-weekly GLP-2 analog with positive Phase III efficacy and safety data in SBS-IF. Its long-acting nature and favorable tolerability profile are expected to support better treatment adherence and potentially expand the number of patients benefiting from GLP-2 therapy, with the ultimate goal of achieving enteral autonomy for patients.

    05

    Financial Strength and Debt Reduction

    Ironwood delivered strong Q2 financial results with $51.3 million in GAAP net income and $83 million in adjusted EBITDA. The company repaid $200 million in convertible notes at maturity using cash on hand and plans to further reduce debt, targeting gross leverage below 1x by the end of 2026, while maintaining resources for apraglutide commercialization.

    06

    Mitigation of Prior Trial Conduct Issues

    Management addressed concerns regarding prior dosing issues in the original STARS trial, confirming that the kit has been dramatically improved and human factor tests conducted to ensure accurate 5mg dose delivery in STARS II. This aims to prevent recurrence of the 3.5mg delivery observed previously and reconfirm the strong efficacy data.

    07

    Leadership Team Additions

    The company welcomed Dr. Jeff Silver as Chief Medical Officer and Head of Research and Drug Development, bringing over 30 years of industry experience. Ron Silver was also introduced as Interim Chief Financial Officer, leveraging his eight years of experience within Ironwood. These appointments are expected to be instrumental in advancing the company's strategic priorities.

    AI-generated summary of the company’s earnings call. Not investment advice.